Weiss A J, Metter G E, Fletcher W S, Wilson W L, Grage T B, Ramirez G
Cancer Treat Rep. 1976 Jul;60(7):813-22.
Adriamycin has been given to 442 patients using the weekly regimen as initially described by Bonadonna et al. Hematologic toxicity and clinical effectiveness have been similar to those described with regimens in which the drug is given every 3 weeks. Stomatitis is more frequent with the weekly regimen than with the usual triweekly regimen. The incidence of electrocardiographic changes and arrhythmias was similar to that reported in other studies. Nine patients received between 500 and 550 mg/m2, nine between 550 and 600 mg/m2, 28 between 600 and 1000 mg/m2, and 22 between 1000 and 2500 mg/m2. None of the patients developed definite evidence of cardiomyopathy although six showed some disturbance of myocardial function. In each of the six patients, factors other than adriamycin cardiotoxicity were believed to play a major role in the myocardial abnormality. The difference between the incidence of cardiomyopathy seen in this series and that previously reported is statistically significant. The reasons for the difference are not clear but are probably related to the schedule that was used.
按照博纳多纳等人最初描述的每周给药方案，已对442例患者使用了阿霉素。血液学毒性和临床疗效与每3周给药方案所描述的相似。与通常的每3周给药方案相比，每周给药方案的口腔炎更为常见。心电图改变和心律失常的发生率与其他研究报告的相似。9例患者接受了500至550mg/m²的剂量，9例接受了550至600mg/m²的剂量，28例接受了600至1000mg/m²的剂量，22例接受了1000至2500mg/m²的剂量。尽管有6例患者出现了一些心肌功能紊乱，但没有患者出现明确的心肌病证据。在这6例患者中，每例患者心肌异常的主要原因被认为是除阿霉素心脏毒性之外的其他因素。本系列中观察到的心肌病发生率与先前报告的发生率之间的差异具有统计学意义。差异的原因尚不清楚，但可能与所采用的给药方案有关。
